Fast, effortless operation and a small footprint make
consistent, accurate in-clinic hematology results accessible to
veterinarians worldwide
WESTBROOK, Maine, Aug. 12, 2020 /CNW/ -- IDEXX Laboratories, Inc.
(NASDAQ: IDXX), a global leader in veterinary diagnostics and
software, announced today the launch of the ProCyte One™ Hematology
Analyzer. The new analyzer's advanced technology delivers
breakthrough workflow simplicity and consistent, accurate results
at the point of care. The ProCyte One Hematology Analyzer is
available today for pre-sale in North
America and for pre-sale in select European markets later
this year, with a global rollout planned for early 2021. The
company expects to begin shipping in volume in the first quarter of
2021.
"ProCyte One reimagines point-of-care hematology with a
radically simple workflow that virtually eliminates complexity
without sacrificing performance," said Jay
Mazelsky, President and Chief Executive Officer of IDEXX
Laboratories. "Sometimes innovation is about making things simple
in order to expand capabilities and advance what's possible."
Packed with leading-edge technology and artificial intelligence,
the ProCyte One Hematology Analyzer transforms point-of-care
hematology with:
- Reference laboratory-quality results, bringing
added confidence to clinical decision-making.
- Reticulocyte counts with every complete blood count
(CBC), serving as an early warning system for a variety of
clinical issues.
- Unprecedented workflow simplicity from automatic quality
control and load-and-go components, delivering results in under 5
minutes.
- Unique pay-per-run and auto-replenishment model that
allows customers to only pay for the tests they run when they run
them, relieving financial stress and the burden of inventory
management.
- Small footprint, freeing up valuable clinical workspace
for other uses.
- Clinical decision support tools, simplifying results
interpretation.
- Sustainable design, featuring recyclable containers to
reduce waste.
ProCyte One also greatly enhances the clinical value of the
entire IDEXX VetLab® suite as hematology and chemistry are
foundational to veterinary medicine in both sick and wellness
visits. The IDEXX VetLab suite with ProCyte One offers
veterinarians a complete picture of their patients' health via
seamlessly integrated diagnostic results available on IDEXX VetLab®
Station and VetConnect® PLUS. Trusted, comprehensive results during
the patient visit enable veterinarians to intervene and treat
patients even faster, accelerating case management, advancing
patient care, deepening client relationships, and offering economic
value.
The IDEXX Hematology portfolio, including the ProCyte One
analyzer, ProCyte Dx® analyzer, and IDEXX Reference Laboratories'
CBC testing, offers the most accurate and comprehensive CBC testing
available.
For more information on the ProCyte One Hematology Analyzer,
visit idexx.com/ProCyteOne.
About IDEXX Laboratories
IDEXX Laboratories, Inc. is a member of the S&P 500® Index
and is a leader in pet healthcare innovation, serving practicing
veterinarians around the world with a broad range of diagnostic and
information technology-based products and services. IDEXX products
enhance the ability of veterinarians to provide advanced medical
care, improve staff efficiency, and build more economically
successful practices. IDEXX is also a worldwide leader in providing
diagnostic tests and information for livestock and poultry, tests
for the quality and safety of water and milk, and point-of-care and
laboratory diagnostics for human medicine. Headquartered in
Maine, IDEXX employs more than
9,000 people and offers products to customers in over 175
countries. For more information about IDEXX,
visit idexx.com.
Note Regarding Forward-Looking Statements
This news release contains or may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements can be identified by
the use of words such as "expects," "may," "anticipates,"
"intends," "would," "will," "plans," "believes," "estimates,"
"should," "project," and similar words and expressions. These
forward-looking statements are intended to provide our current
expectation or forecasts of future events; are based on current
estimates, projections, beliefs, and assumptions; and are not
guarantees of future performance. Actual events or results may
differ materially from those described in the forward-looking
statements, as well as a number of assumptions concerning future
events. These statements are subject to risks, uncertainties,
assumptions and other important factors. Readers are cautioned not
to put undue reliance on such forward-looking statements because
actual results may vary materially from those expressed or implied.
The reports filed by IDEXX pursuant to United States securities laws contain
discussions of some of these risks and uncertainties. IDEXX assumes
no obligation to, and expressly disclaims any obligation to, update
or revise any forward-looking statements, whether as a result of
new information, future events or otherwise. Readers are advised to
review IDEXX's filings with the United States Securities and
Exchange Commission (which are available from the SEC's EDGAR
database at sec.gov and via IDEXX's website at idexx.com).
Media relations
media@idexx.com
Investor relations
John Ravis
1-207-556-8155
Investor-Relations@idexx.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/idexx-launches-groundbreaking-new-procyte-one-hematology-analyzer-with-dramatically-simplified-user-experience-301110520.html
SOURCE IDEXX Laboratories, Inc.